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Abstract 
Aims 
To evaluate the clinical and cost-effectiveness of electric stimulation plus standard pelvic floor 
muscle training compared to standard pelvic floor muscle training alone in women with 
urinary incontinence and sexual dysfunction. 
Methods 
Single centre two arm parallel group randomised controlled trial conducted in a Teaching 
hospital in England. Participants were women presenting with urinary incontinence and 
sexual dysfunction. The interventions compared were electric stimulation versus standard 
pelvic floor muscle training. 
Outcome measures 
included Prolapse and Incontinence Sexual function Questionnaire (PISQ) physical function 
dimension at post-treatment (primary); other dimensions of PISQ, SF-36; EQ-5D, EPAQ, 
resource use, adverse events and cost-effectiveness (secondary outcomes). 
Results 
114 women were randomised (Intervention n = 57; Control group n = 57). 64/114 (56%) 
participants had valid primary outcome data at follow-up (Intervention 30; Control 34). The 
mean PISQ-PF dimension scores at follow-up were 33.1 (SD 5.5) and 32.3 (SD 5.2) for the 
Intervention and Control groups respectively; with the Control group having a higher (better) 
score. After adjusting for baseline score, BMI, menopausal status, time from randomisation 
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There was no differences between the groups in any of the secondary outcomes at follow-up. 
Within this study, the use of electrical stimulation was cost-effective with very small 
incremental costs and quality adjusted life years (QALYs). 
Conclusions 
In women presenting with urinary incontinence in conjunction with sexual dysfunction, 
physiotherapy is beneficial to improve overall sexual function. However no specific form of 
physiotherapy is beneficial over another. 
 
Trial registration ISRCTN09586238. 
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Figure 1: CONSORT Flow chart: Participant flow in the IPSU 
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Completing study or with primary outcome 
(n=37) 
i Excluded from analysis (no primary 
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Analysed (n=34) 
Lost to follow-up (Unable to attend) (n= 12) 
Discontinued intervention (Investigator 
decision) (n=4) 
Allocated to Control (n= 57) 
i Received allocated intervention (n= 53 ) 
i Did not receive allocated intervention 
(adverse effect) (n= 4 ) 
Lost to follow-up (Unable to attend) (n=18) 
Discontinued intervention (Investigator 
decision) (n=6) 
Allocated to intervention (n=57) 
i Received allocated intervention (n=56  ) 
i Did not receive allocated intervention 
(adverse effect) (n=1) 
Completing study or with primary outcome 
(n=32) 
i Excluded from analysis (no primary 
outcome) (n=2) 
Analysed (n=30) 
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Analysis 
Follow-Up 
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Table 1 Demographics and characteristics of participants at baseline 
 Group 
Standard physiotherapy Electrical Stimulation Total 
n % n % n % 
Age Mean (SD) 45.5 (9.8) --- 45.8( 9.4) --- 45.6(9.5) -- 
Menopausal Status No 
Yes 
Total 
41 72 40 70 81 71 
16 28 17 30 33 29 
57 100 57 100 114 100 
Parity 0 2 4 0 0 2 2 
 1 11 19 13 23 24 21 
 2 32 56 24 42 56 49 
 3 6 11 10 18 16 14 
 4 3 5 8 14 11 10 
 5 2 4 2 4 4 4 
 8 1 2 0 0 1 1 
 Total 57 100 57 100 114 100 
Ethnicity English/Welsh/Scottish/Nort
hern Ireland/British 
56 98 56 98 112 98 
 Any Asian Background 0 0 1 2 1 1 
 Any other black/African/ 
Caribbean 
1 2 0 0 1 1 
 Total 57 100 57 100 114 100 
Hysterectomy No 49 86 47 82 95 84 
 Yes 8 14 10 18 18 16 
 Total 57 100 57 100 113 100 
Regular Menstrual Cycle No 7 12 9 16 16 14 
 Yes 27 47 23 40 50 44 
Dysmenorrhoea No 30 53 23 40 53 47 
 Yes 5 19 8 14 13 11 
Dyspareunia No 48 84 48 84 96 84 
 Yes 4 7 7 12 11 10 
Oxford Scale grade 0 1 2 5 9 6 5 
 1 23 40 14 25 37 33 
 2 30 53 33 58 63 55 
 3 0 0 1 2 1 1 
 Not Done 3 5 3 5 6 6 
 Total 57 100 57 100 114 100 
BMI Mean (SD) 28.4 (5.5) -- 30.7 (7.4) -- 29.5 
(6.6) 
-- 
 Group 
Standard physiotherapy 
(n=57) 
Electrical Stimulation 
(n=57) 
Total 
(n=114) 
PISQ behaviour emotive domain N (%) 55 (96.5%) 50 (87.7%) 105 (92.1%) 
Mean (SD) 38.2 (8.6) 34.1 (10.2) 36.2 (9.6) 
PISQ Physical Factor N (%) 55 (96.5%) 49 (86.0%) 104 (91.2%) 
Mean (SD) 29.7 (5.7) 27.7 (5.6) 28.7 (5.8) 
PISQ Partner related  N (%) 54 (94.7%) 49 (86.0%) 103 (90.4%) 
Mean (SD) 20.1 (2.0) 19.0 (3.1) 19.6 (2.6) 
PISQ Total Score N (%) 54 (94.7%) 48 (84.2%) 102 (89.5%) 
Mean (SD) 88.2 (12.7) 80.7 (14.3) 84.7 (14.0) 
EQ5D Score N (%) 55 (96.49%) 51 (89.47%) 106 (92.98%) 
Mean (SD) 0.79 (0.20) 0.78 (0.15) 0.78 (0.18) 
SF36 Physical Component scale N (%) 55 (96.5%) 51 (89.5%) 106 (93.0%) 
Mean (SD) 16.4 (39.1) 20.2 (36.6) 18.2 (37.8) 
SF36 Mental component scale N (%) 55 (96.5%) 51 (89.5%) 106 (93.0%) 
Mean (SD) 18.8 (37.8) 22.7 (37.4) 20.7 (37.5) 
ePAQ PF : General Sex Life N (%) 52 (91.2%) 56 (98.2%) 108 (94.7%) 
Mean (SD) 41.4 (27.4) 50.9 (25.3) 46.3 (26.6) 
 
Table 2: Baseline characteristics by treatment group and missing data status 
______________________________________________________________________________________________________________________ 
Characteristic Missing PISQ physical dimension 
     
Complete PISQ physical dimension 
     
 
Control 
 
Intervention 
 
All 
 
Control 
 
Intervention 
 
All 
 
 
(n=23) 
 
(n=27) 
 
(n=50) 
 
(n=34) 
 
(n=30) 
 
(n=64) 
 
 
n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) 
Age 23 45.0 (9.9) 27 44.7 (9.7) 50 44.8 (9.7) 34 45.7 (9.8) 30 46.7 (9.1) 64 46.2 (9.4) 
BMI 21 28.3 (5.8) 24 31.1 (6.4) 45 29.8 (6.2) 33 28.4 (5.4) 28 30.4 (8.2) 61 29.3 (6.9) 
PISQ behaviour/emotion factor 21 37.1 (9.6) 21 32.5 (11.8) 42 34.8 (10.9) 34 38.8 (8.1) 29 35.2 (8.9) 63 37.2 (8.6) 
PISQ physical factor 21 28.4 (6.0) 21 26.5 (5.5) 42 27.4 (5.7) 34 30.5 (5.5) 28 28.5 (5.7) 62 29.6 (5.6) 
PISQ partner related factor 20 20.1 (2.1) 21 19.0 (3.1) 41 19.6 (2.7) 34 20.2 (2.0) 28 19.0 (3.2) 62 19.6 (2.6) 
PISQ total score 20 86.0 (13.6) 21 78.1 (15.1) 41 81.9 (14.8) 34 89.5 (12.2) 27 82.7 (13.6) 61 86.5 (13.2) 
EQ5D score 21 0.79 (0.13) 22 0.77 (0.18) 43 0.78 (0.16) 34 0.79 (0.24) 29 0.79 (0.13) 63 0.79 (0.19) 
SF-36 Physical Component Scale 21 15.9 (38.7) 23 10.6 (36.7) 44 13.1 (37.3) 34 16.8 (39.9) 28 28.0 (35.2) 62 21.9 (38.0) 
SF-36 Mental Component Scale 21 16.6 (37.9) 23 11.4 (36.2) 44 13.9 (36.7) 34 20.1 (38.2) 28 32.1 (36.4) 62 25.5 (37.5) 
ePAQ PF: General sex life    18 44.1 (27.1) 26 50.1 (24.6) 44 47.6 (25.5) 34 39.9 (27.8) 30 51.7 (26.3) 64 45.5 (27.5) 
_____________________________________________________________________________________________________________________________ 
Characteristic 
 
Missing PISQ physical dimension 
  
Complete PISQ physical dimension 
  
  
Control Intervention All Control Intervention All 
  
(n=23) (n=27) (n=50) (n=34) (n=30) (n=64) 
Ethnicity English / Welsh / Scottish / Northern Irish / British 23 (100.0%) 27 (100.0%) 50 (100.0%) 33 (97.1%) 29 (96.7%) 62 (96.9%) 
 Any other Asian background 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (3.3%) 1 (1.6%) 
 Any other Black / African / Caribbean Background 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (2.9%) 0 (0.0%) 1 (1.6%) 
        
Parity 0 2 (8.7%) 0 (0.0%) 2 (4.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
__________________________________________________________________________________________________________________________ 
 1 4 (17.4%) 6 (22.2%) 10 (20.0%) 7 (20.6%) 7 (23.3%) 14 (21.9%) 
 2 11 (47.8%) 9 (33.3%) 20 (40.0%) 21 (61.8%) 15 (50.0%) 36 (56.3%) 
 3 2 (8.7%) 6 (22.2%) 8 (16.0%) 4 (11.8%) 4 (13.3%) 8 (12.5%) 
 4 2 (8.7%) 6 (22.2%) 8 (16.0%) 1 (2.9%) 2 (6.7%) 3 (4.7%) 
 5 1 (4.3%) 0 (0.0%) 1 (2.0%) 1 (2.9%) 2 (6.7%) 3 (4.7%) 
 8 1 (4.3%) 0 (0.0%) 1 (2.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Hysterectomy No 20 (87.0%) 23 (85.2%) 43 (86.0%) 28 (82.4%) 24 (80.0%) 52 (81.3%) 
 Yes 3 (13.0%) 4 (14.8%) 7 (14.0%) 5 (14.7%) 6 (20.0%) 11 (17.2%) 
Menopausal No 18 (78.3%) 21 (77.8%) 39 (78.0%) 23 (67.6%) 19 (63.3%) 42 (65.6%) 
 Yes 5 (21.7%) 6 (22.2%) 11 (22.0%) 11 (32.4%) 11 (36.7%) 22 (34.4%) 
        
        
Regular menstrual cycle No 4 (17.4%) 7 (25.9%) 11 (22.0%) 3 (8.8%) 2 (6.7%) 5 (7.8%) 
 Yes 11 (47.8%) 11 (40.7%) 22 (44.0%) 16 (47.1%) 12 (40.0%) 28 (43.8%) 
Dysmenorrhoea No 14 (60.9%) 12 (44.4%) 26 (52.0%) 16 (47.1%) 11 (36.7%) 27 (42.2%) 
 Yes 2 (8.7%) 6 (22.2%) 8 (16.0%) 3 (8.8%) 2 (6.7%) 5 (7.8%) 
Dyspareunia No 18 (78.3%) 23 (85.2%) 41 (82.0%) 30 (88.2%) 25 (83.3%) 55 (85.9%) 
 Yes 2 (8.7%) 3 (11.1%) 5 (10.0%) 2 (5.9%) 4 (13.3%) 6 (9.4%) 
Oxford scale grade 0 1 (4.3%) 3 (11.1%) 4 (8.0%) 0 (0.0%) 2 (6.7%) 2 (3.1%) 
 1 7 (30.4%) 8 (29.6%) 15 (30.0%) 16 (47.1%) 6 (20.0%) 22 (34.4%) 
 2 12 (52.2%) 11 (40.7%) 23 (46.0%) 18 (52.9%) 22 (73.3%) 40 (62.5%) 
 3 0 (0.0%) 1 (3.7%) 1 (2.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Table 3 Overall change in PISQ following physiotherapy (both types of treatment combined) 
 
Outcome 
 n Mean change (SD) 95% CI p-value 
PISQ behaviour/emotion 
factor 63 2.3 (6.8) 0.6 to 4.0 0.009 
PISQ physical factor 62 3.2 (6.2) 1.6 to 4.8 <0.001 
PISQ partner related factor 62 0.5 (2.2) -0.1 to 1.0 0.094 
PISQ total score 61 5.9 (11.8) 2.9 to 8.9 <0.001 
 
 
 
 
 
 
Table 4: Primary Outcomes: mean difference of PISQ domains between Control and Intervention 
 
 Control Intervention Unadjusted Adjusted* 
Outcome n 
Mean 
(SD) n 
Mean 
(SD) 
N 
analysis 
mean 
difference 95% CI p-value 
N 
analysis 
mean 
difference 
95% 
CI p-value 
PISQ physical 
factor 34 
33.1 
(5.5) 30 
32.3 
(5.2) 64 -0.8 
-3.5 to 
1.9 0.572 60 -1 
-4.0 to 
1.9 0.474 
PISQ 
behaviour/emotio
n factor 
34 40.8 
(8.7) 
30 37.4 
(11.2) 
64 -3.4 -8.4 to 
1.6 
0.176 60 1.9 -2.1 to 
5.9 
0.345 
PISQ partner 
related factor 
34 20.4 
(2.0) 
30 19.6 
(3.0) 
64 -0.8 -2.1 to 
0.4 
0.202 59 0.4 -0.6 to 
1.5 
0.412 
PISQ total score 34 94.2 
(12.5) 
30 89.2 
(15.8) 
64 -5 -12.1 
to 2.1 
0.165 59 1.1 -5.9 to 
8.2 
0.748 
 
*Adjusted for baseline score, BMI, menopausal status, time from randomisation and oxford scale 
The PISQ-physical factor is scored on a 0 to 40 scale with a higher scoring indicating better sexual functioning 
 
 
 
 
 
